Liposome |
Spherical formed vesicles which consist of phospholipid bilayers |
50-400 nm |
Water soluble |
|
Biodegradable |
|
Use of EPR effect |
|
Modifiable surface |
|
Actively targeting by surface modification |
|
Protection of the payload |
|
Formed out of lipids |
|
Amphiphile |
|
Possibility to form multilamilarity |
|
Prolonged systemic exposure |
|
Rapid clearance by RES (if not pegylated) |
|
Potency to modify drug resistance |
|
Possible immune reactions |
|
Limited stability |
|
Difficulties in drug loading |
Micelle |
Spherical formed drug delivery system with a hydrophobic core and a hydrophilic shell |
10-100 nm |
Water soluble |
|
Biodegradable |
|
Use of EPR effect |
|
Modifiable surface |
|
Actively targeting by surface modification |
|
Protection of the payload |
|
Formed out of polymers or lipids |
|
Prolonged systemic exposure |
|
Small uptake by RES |
|
Initial burst of drug release |
|
Highly permeable shell |
|
Low sustained controlled drug release |
|
Low immunogenicity |
Polymeric Nanoparticle |
Matrix of polymers which binds drugs to a side chain of a polymer with a linker |
10-1000 nm |
Water soluble |
|
Biodegradable |
|
Use of EPR effect |
|
Modifiable surface |
|
Actively targeting by surface modification |
|
Protection of the payload |
|
Formed out of synthetic or natural polymers |
|
Variety of composition possibilities |
|
(ie, wide variation in polymers and copolymers) |
|
Possibility to form double walled particles |
|
Prolonged systemic exposure |
|
Initial burst of drug release |
|
Sustained controlled drug release |
|
Low immunogenicity |
|
Stable during storage |